News

Printer Friendly Version View printer-friendly version
<< Back
Array BioPharma Announces Analyst Event and Live Webcast in New York City

BOULDER, Colo.--(BUSINESS WIRE)--Nov. 28, 2006--Array BioPharma Inc. (NASDAQ: ARRY) today announced that it will host an Analyst Event on Tuesday, December 5, 2006, beginning at 8:30 a.m. in New York City.

The event will include updates on the Company's drug development programs including: ARRY-886 (AZD6244) - MEK inhibitor for Cancer, ARRY-543 - ErbB-2 / EGFR inhibitor for Cancer, ARRY-797 - p38 inhibitor for Cancer & Inflammation, ARRY-162 - MEK inhibitor for Inflammation, and ARRY-520 - KSP inhibitor for Cancer. A panel discussion and Q&A will follow the presentations.

Investment professionals interested in attending Array's Analyst Event should contact Tricia Haugeto at 303-386-1193 or ir@arraybiopharma.com. The public is welcome to participate in the event over the phone or internet. The webcast will include the slide presentations and will be accessible from the Array BioPharma website.

Presenters:     Robert E. Conway, Chief Executive Officer, Array
                BioPharma

                Brent Vose, Ph.D., Vice President & Head of Oncology &
                Infection Therapy Area, R&D, AstraZeneca

                Karen Gelmon, M.D., Professor of Medicine, University
                of British Columbia & Medical Oncologist, British
                Columbia Cancer Agency

                Kevin Koch, Ph.D., President & Chief Scientific
                Officer, Array BioPharma

                April Teitelbaum, M.D., Vice President, Clinical
                Development - Oncology, Array BioPharma

Date:           Tuesday, December 5, 2006
Time:           8:30 - 11:30 a.m. Eastern Time
Webcast:        www.arraybiopharma.com
Dial In:        866-356-3377 or 617-597-5392
Password:       57272882

About Array BioPharma:

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life-threatening and debilitating diseases. Our proprietary drug development pipeline is focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas. For more information on Array, please go to www.arraybiopharma.com.


    CONTACT: Array BioPharma Inc. 
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com

SOURCE: Array BioPharma Inc.